TITLE

A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis

AUTHOR(S)
Tilg, H.; Vogelsang, H.; Ludwiczek, O.; Lochs, H.; Kaser, A.; Colombel, J. -F.; Ulmer, H.; Rutgeerts, P.; Krüger, S.; Cortot, A.; D'Haens, G.; Harrer, M.; Gasche, C.; Wrba, F.; Kuhn, I.; Reinisch, W.
PUB. DATE
December 2003
SOURCE
Gut;Dec2003, Vol. 52 Issue 12, p1728
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Pilot studies of interferon cc (IFN-α) suggest a high remission rate in the treatment of active ulcerative colitis. We evaluated the safely of pegylated interferon α (PegIFN) and its role in induction of remission in patients with active ulcerative colitis, in a multicentre placebo controlled trial. Methods: Sixty patients with a clinical activity score (Cal) of >6 were randomised to receive placebo (n=20), Pe9IFN 0.5 μg/kg (n= 19), or PegIFN 1.0 μg/kg body weight (n=21) once weekly (Peglntron; Schering-Plough, USA) over 12 weeks. Patients receiving 5-aminosalicylates, steroids, and/or azathioprine in stable dosages were included. Results: Serious adverse events were seen in none of the placebo patients, in 3/19 patients in the PegIFN 0.5 μg/kg group (hospitalisation due to disease flare up n = 3), and in 3/21 in the PegIFN 1.0 μg/kg group (hospitalisation due to disease Hare up n = 1; thrombosis n = 1; grand mal seizure n = 1). Otherwise, we observed only minor IFN-α side effects. Clinical remission rates at week 12 (Cal ⩽ 4) were 7/20(35%) in the placebo, 9/19 (47%) in the PegIFN 0.5 μg/kg group, and 7/21 (33%) in the PeglFN 1 .0 μg/kg group (NS). Early withdrawal from the study was observed in 11/20 placebo patients, in 6/19 in the PeglFN 0.5 μg/kg group, and in 10/21 in the PegIFN 1.0 μg/kg group, mainly due to lack of efficacy. The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day o v85). Conclusions: PegIFN is safe but not effective, at the dosages used, in patients with ulcerative colitis.
ACCESSION #
12940912

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics